{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-25-000099","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.463315+00:00","generated_at":"2026-05-17T20:42:33.439791+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elicio Therapeutics announces IDMC positive recommendation to continue Phase 2 pancreatic cancer trial to final analysis","bullets":["IDMC recommended AMPLIFY-7P trial continue to final analysis without modifications based on pre-specified interim review of safety and efficacy.","Final disease-free survival analysis anticipated in Q4 2025; company remains blinded to trial outcomes.","Cash runway extends into Q1 2026, past the expected final DFS readout.","Elicio previously reached FDA alignment on key elements of planned pivotal Phase 3 study design.","ELI-002 7P is an off-the-shelf immunotherapy targeting seven KRAS mutations in pancreatic ductal adenocarcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-25-000099","json":"https://secwatch.observer/filing/0001601485-25-000099.json","markdown":"https://secwatch.observer/filing/0001601485-25-000099.md","text":"https://secwatch.observer/filing/0001601485-25-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000099/0001601485-25-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000099/angn-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:42:33.439791+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}